3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
7
Lymphoid
5
Thoracic
4
Sarcoma
3
Plasma cell
2
Other hematologic neoplasm
2
Gynecologic
2
Tumor-Agnostic
1
Head & Neck
1
Conditions
Ovarian Neoplasms
2
Ovarian Germ Cell Cancer
1
Interventions
Paclitaxel
150
Carboplatin
110
Cisplatin
95
Bevacizumab
42
Topotecan
39
Gemcitabine
38
liposomal doxorubicin
34
Radiotherapy
29
Doxorubicin
27
Brachytherapy
26
Taxes
24
pembrolizumab
20
olaparib
20
Drug Therapy
20
Hyperthermic Intraperitoneal Chemotherapy
16
Chemotherapy, Adjuvant
16
human papillomavirus vaccine, L1 type 16, 18
15
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
Docetaxel
13
Neoadjuvant Therapy
12
Platinum
10
niraparib
9
Radiation
9
1,2-diaminocyclohexaneplatinum II citrate
9
Vaccines, Synthetic
8
Surgical Procedures, Operative
8
atezolizumab
7
Specimen Handling
7
Papillomavirus Vaccines
7
Letrozole
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
etoposide phosphate
×
Gynecologic
×
Clear all
NCT02429687
2023-04-25
MOGCT-01
Shandong University
Phase 3
Recruiting
129 enrolled
NCT02429700
2023-04-25
SCST-01
Shandong University
Phase 3
Recruiting
132 enrolled